vs
Amneal Pharmaceuticals, Inc.（AMRX）とRoyalty Pharma plc（RPRX）の財務データ比較。上の社名をクリックして会社を切り替えられます
Amneal Pharmaceuticals, Inc.の直近四半期売上が大きい（$814.3M vs $622.0M、Royalty Pharma plcの約1.3倍）。Royalty Pharma plcの純利益率が高く（34.4% vs 4.3%、差は30.1%）。Amneal Pharmaceuticals, Inc.の前年同期比売上増加率が高い（11.5% vs 4.8%）。過去8四半期でAmneal Pharmaceuticals, Inc.の売上複合成長率が高い（11.1% vs 4.6%）
アムニールファーマシューティカルズは米国の上場製薬企業で、後発医薬品と専門医薬品の開発・製造・流通を事業の柱としています。本社はニュージャージー州ブリッジウォーターに位置し、米国最大級の後発医薬品メーカーの1つです。
当社は米国マサチューセッツ州ケンブリッジに本社を置く臨床段階のバイオ医薬品企業で、形質転換成長因子β（TGF-β）スーパーファミリーに属するタンパク質を調節する医薬品の開発を主な事業としている。同タンパク質は赤血球、筋肉、骨、血管などの細胞や組織の成長・修復に根本的な役割を果たしている。
AMRX vs RPRX — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $814.3M | $622.0M |
| 純利益 | $35.1M | $214.2M |
| 粗利率 | 36.5% | — |
| 営業利益率 | 13.8% | 62.4% |
| 純利益率 | 4.3% | 34.4% |
| 売上前年比 | 11.5% | 4.8% |
| 純利益前年比 | 212.9% | 2.9% |
| EPS（希薄化後） | $0.10 | $0.49 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $814.3M | $622.0M | ||
| Q3 25 | $784.5M | $609.3M | ||
| Q2 25 | $724.5M | $578.7M | ||
| Q1 25 | $695.4M | $568.2M | ||
| Q4 24 | $730.5M | $593.6M | ||
| Q3 24 | $702.5M | $564.7M | ||
| Q2 24 | $701.8M | $537.3M | ||
| Q1 24 | $659.2M | $568.0M |
| Q4 25 | $35.1M | $214.2M | ||
| Q3 25 | $2.4M | $288.2M | ||
| Q2 25 | $22.4M | $30.2M | ||
| Q1 25 | $12.2M | $238.3M | ||
| Q4 24 | $-31.1M | $208.2M | ||
| Q3 24 | $-156.0K | $544.0M | ||
| Q2 24 | $6.0M | $102.0M | ||
| Q1 24 | $-91.6M | $4.8M |
| Q4 25 | 36.5% | — | ||
| Q3 25 | 34.9% | — | ||
| Q2 25 | 39.5% | — | ||
| Q1 25 | 36.8% | — | ||
| Q4 24 | 36.0% | — | ||
| Q3 24 | 38.4% | — | ||
| Q2 24 | 35.6% | — | ||
| Q1 24 | 36.1% | — |
| Q4 25 | 13.8% | 62.4% | ||
| Q3 25 | 9.0% | 70.1% | ||
| Q2 25 | 15.4% | 36.3% | ||
| Q1 25 | 14.4% | 94.0% | ||
| Q4 24 | 10.4% | 60.9% | ||
| Q3 24 | 12.6% | — | ||
| Q2 24 | 13.6% | 50.2% | ||
| Q1 24 | -1.6% | -13.0% |
| Q4 25 | 4.3% | 34.4% | ||
| Q3 25 | 0.3% | 47.3% | ||
| Q2 25 | 3.1% | 5.2% | ||
| Q1 25 | 1.8% | 41.9% | ||
| Q4 24 | -4.3% | 35.1% | ||
| Q3 24 | -0.0% | 96.3% | ||
| Q2 24 | 0.9% | 19.0% | ||
| Q1 24 | -13.9% | 0.8% |
| Q4 25 | $0.10 | $0.49 | ||
| Q3 25 | $0.01 | $0.67 | ||
| Q2 25 | $0.07 | $0.07 | ||
| Q1 25 | $0.04 | $0.55 | ||
| Q4 24 | $-0.10 | $0.46 | ||
| Q3 24 | $0.00 | $1.21 | ||
| Q2 24 | $0.02 | $0.23 | ||
| Q1 24 | $-0.30 | $0.01 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.0M | $618.7M |
| 総負債低いほど良い | $2.6B | $9.0B |
| 株主資本純資産 | $-70.8M | $9.7B |
| 総資産 | $3.7B | $19.6B |
| 負債/資本比率低いほどレバレッジが低い | — | 0.92× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.0M | $618.7M | ||
| Q3 25 | $201.2M | $938.9M | ||
| Q2 25 | $71.5M | $631.9M | ||
| Q1 25 | $59.2M | $1.1B | ||
| Q4 24 | $110.6M | $929.0M | ||
| Q3 24 | $74.0M | $950.1M | ||
| Q2 24 | $43.8M | $1.8B | ||
| Q1 24 | $46.5M | $843.0M |
| Q4 25 | $2.6B | $9.0B | ||
| Q3 25 | $2.6B | $8.9B | ||
| Q2 25 | $2.2B | $8.0B | ||
| Q1 25 | $2.2B | $7.6B | ||
| Q4 24 | $2.4B | $7.6B | ||
| Q3 24 | $2.4B | $7.6B | ||
| Q2 24 | $2.4B | $7.6B | ||
| Q1 24 | $2.4B | $6.1B |
| Q4 25 | $-70.8M | $9.7B | ||
| Q3 25 | $-109.5M | $9.6B | ||
| Q2 25 | $-112.1M | $9.5B | ||
| Q1 25 | $-131.7M | $9.8B | ||
| Q4 24 | $-109.3M | $10.3B | ||
| Q3 24 | $-93.4M | $10.3B | ||
| Q2 24 | $-57.5M | $9.8B | ||
| Q1 24 | $-63.7M | $9.9B |
| Q4 25 | $3.7B | $19.6B | ||
| Q3 25 | $3.6B | $19.3B | ||
| Q2 25 | $3.4B | $18.3B | ||
| Q1 25 | $3.4B | $17.6B | ||
| Q4 24 | $3.5B | $18.2B | ||
| Q3 24 | $3.5B | $18.0B | ||
| Q2 24 | $3.5B | $17.7B | ||
| Q1 24 | $3.5B | $16.1B |
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $130.3M | $827.1M |
| フリーキャッシュフロー営業CF - 設備投資 | $108.5M | — |
| FCFマージンFCF / 売上 | 13.3% | — |
| 設備投資強度設備投資 / 売上 | 2.7% | — |
| キャッシュ転換率営業CF / 純利益 | 3.72× | 3.86× |
| 直近12ヶ月FCF直近4四半期 | $269.9M | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $130.3M | $827.1M | ||
| Q3 25 | $118.5M | $702.6M | ||
| Q2 25 | $83.8M | $364.0M | ||
| Q1 25 | $7.4M | $596.1M | ||
| Q4 24 | $118.1M | $742.5M | ||
| Q3 24 | $141.8M | $703.6M | ||
| Q2 24 | $39.7M | $658.2M | ||
| Q1 24 | $-4.4M | $664.6M |
| Q4 25 | $108.5M | — | ||
| Q3 25 | $106.2M | — | ||
| Q2 25 | $61.0M | — | ||
| Q1 25 | $-5.8M | — | ||
| Q4 24 | $102.9M | — | ||
| Q3 24 | $124.8M | — | ||
| Q2 24 | $29.0M | — | ||
| Q1 24 | $-13.6M | — |
| Q4 25 | 13.3% | — | ||
| Q3 25 | 13.5% | — | ||
| Q2 25 | 8.4% | — | ||
| Q1 25 | -0.8% | — | ||
| Q4 24 | 14.1% | — | ||
| Q3 24 | 17.8% | — | ||
| Q2 24 | 4.1% | — | ||
| Q1 24 | -2.1% | — |
| Q4 25 | 2.7% | — | ||
| Q3 25 | 1.6% | — | ||
| Q2 25 | 3.2% | — | ||
| Q1 25 | 1.9% | — | ||
| Q4 24 | 2.1% | — | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | 1.5% | — | ||
| Q1 24 | 1.4% | — |
| Q4 25 | 3.72× | 3.86× | ||
| Q3 25 | 50.00× | 2.44× | ||
| Q2 25 | 3.74× | 12.06× | ||
| Q1 25 | 0.61× | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | — | 1.29× | ||
| Q2 24 | 6.62× | 6.45× | ||
| Q1 24 | — | 139.10× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMRX
| Oral Solid | $188.7M | 23% |
| Distribution Service | $107.7M | 13% |
| Central Nervous System | $104.8M | 13% |
| Government Label | $86.8M | 11% |
| Other Dosage Forms | $68.2M | 8% |
| Transdermal | $56.1M | 7% |
| Hormonal Allergy | $47.6M | 6% |
| Ephinephrine Auto Injector | $39.1M | 5% |
| Injectable | $37.4M | 5% |
| Other | $33.6M | 4% |
| Biosimilar | $29.4M | 4% |
| Selling General And Administrative Expenses | $14.9M | 2% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
